NEUROCRINE BIOSCIENCES INC

Neurocrine Biosciences insider sale reveals governance, equity‑compensation strategy and market positioning for investors, highlighting confidence in its neuro‑therapeutic pipeline.

Neurocrine Biosciences (NBIX) sees a 40% upside from earnings revisions and a strong neuro‑oncology pipeline, but faces regulatory and reimbursement risks that investors must monitor.

Neurocrine Biosciences’ $2.9 billion acquisition of Soleno Therapeutics expands its neuro‑oncology pipeline, adding precision ADCs like SLO‑101 and SLO‑204 with promising early efficacy and a strong regulatory roadmap.

Neurocrine’s $2.9 B acquisition of Soleno adds FDA‑approved VYKAT XR for Prader‑Willi, expanding its rare‑disease portfolio with proven efficacy and a strong safety profile.

Neurocrine’s $2.9 B acquisition of Soleno Therapeutics unlocks Vykat XR’s rare‑disorder revenue, boosting margins and diversifying into a high‑growth, low‑competition market.

Neurocrine Biosciences will host a live investor webinar on March 17, revealing CNS‑forum insights, pipeline progress, and strategic partnerships for neurological & endocrine therapies.

Neurocrine Biosciences reports 29 % Q4 revenue growth driven by Nexvia launch, strong EPS lift, and a strategic roadmap to beat patent cliffs and boost 2026 earnings.

Neurocrine Biosciences shows strong market access and pricing for Piqray®, positioning itself for growth in the $60 billion neuro‑psychiatric sector while navigating patent cliffs and limited pipeline depth.

Neurocrine’s Phase 3 KINECT‑DCP trial of valbenazine for dyskinetic cerebral palsy shows consistent safety but no significant efficacy, highlighting challenges in treating CP-related chorea.

Neurocrine Biosciences’ Phase 3 valbenazine trial for dyskinetic cerebral palsy failed to meet its primary endpoint, revealing key lessons for rare‑disease drug development and investor strategy.